Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives $14.60 Consensus Price Target from Analysts

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $14.60.

BDTX has been the topic of a number of research reports. HC Wainwright raised their price target on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, March 18th. Stifel Nicolaus lowered their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Wall Street Zen raised Black Diamond Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Finally, Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th.

Institutional Trading of Black Diamond Therapeutics

Several hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp raised its position in Black Diamond Therapeutics by 46.1% in the fourth quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company's stock worth $443,000 after acquiring an additional 65,341 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Black Diamond Therapeutics by 7.9% during the 4th quarter. Wellington Management Group LLP now owns 221,236 shares of the company's stock worth $473,000 after purchasing an additional 16,279 shares during the period. Barclays PLC grew its stake in shares of Black Diamond Therapeutics by 10.7% during the 4th quarter. Barclays PLC now owns 86,545 shares of the company's stock worth $186,000 after purchasing an additional 8,394 shares during the period. D. E. Shaw & Co. Inc. purchased a new position in shares of Black Diamond Therapeutics in the 4th quarter valued at about $37,000. Finally, Sei Investments Co. acquired a new stake in shares of Black Diamond Therapeutics in the fourth quarter valued at about $49,000. 95.47% of the stock is owned by institutional investors and hedge funds.

Black Diamond Therapeutics Stock Up 0.4%

NASDAQ:BDTX traded up $0.01 during trading hours on Monday, reaching $2.33. 911,083 shares of the company's stock were exchanged, compared to its average volume of 1,536,905. Black Diamond Therapeutics has a 1-year low of $1.20 and a 1-year high of $6.75. The firm has a market capitalization of $132.48 million, a price-to-earnings ratio of 38.83 and a beta of 2.71. The company has a 50-day moving average of $1.92 and a 200 day moving average of $2.04.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.